Target intelligence / Profile preview

Phospholipase C eta-1 (PLCH1)

Target
PLCH1
Molecular classification
Enzyme, Phosphoinositide-specific phospholipase C family, EF-hand domain containing protein, C2 domain containing protein
01

Overview

Phospholipase C eta-1 (PLCH1) is an enzyme of the phosphoinositide-specific phospholipase C family, involved in the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) to generate the second messengers diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), a process critical for intracellular calcium signaling. PLCH1 features conserved domains typical of the PLC-eta family, including pleckstrin homology, EF-hand, C2, and catalytic X and Y domains, and is predominantly expressed in neuronal tissues and lung. Functional studies indicate essential roles in central nervous system signaling and neurodevelopment, with pathogenic variants causing holoprosencephaly spectrum disorders. Polymorphisms in PLCH1 are also associated with increased lung cancer risk, highlighting its involvement in both physiological signaling and disease pathogenesis.

Other names
KIAA1069PLCL3PLC-eta-1PLC-L3PLCeta1Phosphoinositide phospholipase C-eta-1Phospholipase C-like protein 3HPE14MGC117152DKFZp434C1372phospholipase C-eta1aphospholipase C-eta1b
02

Biological functions

Signal transductionCalcium signalingHydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) to generate second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG)Neurodevelopment
03

Disease associations

Neurodevelopmental disorders (notably holoprosencephaly spectrum)Cancer (association with lung cancer risk)
04

Safety considerations

Pathogenic mutations in PLCH1 cause loss of function with significant effects on prenatal neurodevelopment, resulting in congenital brain malformations such as holoprosencephaly and hydrocephalus
05

Biomarkers

Genetic variants of PLCH1 as potential biomarkers for holoprosencephaly and possibly lung cancer risk

Beyond the preview

Go deeper on Phospholipase C eta-1 (PLCH1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phospholipase C eta-1 (PLCH1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call